It is worth noting that a randomized, open‐label, phase III trial, ADJUVANT22 demonstrated patients with resected EGFR‐mutant, stage II–IIIA NSCLC, adjuvant gefitinib prolonged recurrence time and showed advantages over VP chemotherapy (28.7 versus 18.0 months; P = .0054). Here, EGFR is linked to non-small cell lung carcinoma.